The sorry saga of the statins in New Zealand - Pharmacopolitics versus patient care

New Zealand Medical Journal

Volumn 116, Issue 1170, 2003, Pages

  Begg, Evan J ^a   Sidwell, Andrew I ^a   Gardiner, Sharon J ^a   Nicholls, M Gary ^a   Scott, Russell S ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BENOXAPROFEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MIBEFRADIL; PRACTOLOL; PRAVASTATIN; QUINAPRIL; SIMVASTATIN; INDOLE DERIVATIVE; MONOUNSATURATED FATTY ACID;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG CHOICE; DRUG COST; DRUG INDUSTRY; DRUG MEGADOSE; DRUG METABOLISM; EVIDENCE BASED MEDICINE; FOOD DRUG INTERACTION; HEALTH CARE; HUMAN; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; NEW ZEALAND; PATIENT CARE; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; SIDE EFFECT; ARTICLE; ECONOMICS; FEE; GOVERNMENT; HEALTH INSURANCE; INSURANCE; ORGANIZATION AND MANAGEMENT; POLITICS; PUBLIC HEALTH;

DRUG INDUSTRY; FATTY ACIDS, MONOUNSATURATED; FEES, PHARMACEUTICAL; GOVERNMENT AGENCIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; INSURANCE COVERAGE; INSURANCE, PHARMACEUTICAL SERVICES; NATIONAL HEALTH PROGRAMS; NEW ZEALAND; POLITICS; PRAVASTATIN; RATE SETTING AND REVIEW; SIMVASTATIN;

EID: 0037436674     PISSN: 11758716     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
4. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57.
5. Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 1998;19:26-37.
6. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998;64:477-83.
7. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther 1999;66:118-27.
8. Braae R, McNee W, Moore D. Managing pharmaceutical expenditure while increasing access. The pharmaceutical management agency (PHARMAC) experience. Pharmacoeconomics 1999;16:649-60.
9. Thomas MC, Mann J, Williams S. The impact of reference pricing on clinical lipid control. NZ Med J 1998;111:292-4.
10. Thomas M, Mann J. Increased thrombotic vascular events after change of statin. Lancet 1998;352:1830-1.
11. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
12. Serruys PW, Foley DP, Jackson G, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after a successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Euro Heart J 1999;20:58-69.
13. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999;341:70-6.
14. Schwartz GG. Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischaemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-8.
15. Furberg CD, Herrington DM, Psaty BM. Are drugs within a class interchangeable? Lancet 1999;354:1202-4.
16. Medical Council Ethical Guidelines for doctor's duties in an environment of competition or resource limitation. NZ Med J 2000;113:65-6.
17. Pharmacology Management Agency Ltd (PHARMAC) Drug Scene. Views: It's time we doctors took a new, fresh look at our ethics. Sept 1997.